touchENDOCRINOLOGY caught up with Prof Gian Paolo Fadini (University Hospital of Padova, Italy) virtually during the EASD Annual Meeting 2021 conference to discuss the real-world data from the RESTORE-2 study.
Questions
1. What have randomized controlled trials taught us about the efficacy and safety of second-generation basal insulins? (00:18-01:31)
2. What were the aims, design and inclusion criteria of your study? (01:31-02:44)
3. What were the baseline characteristics of the study cohort? (02:44-03:34)
4. What were the primary and secondary outcome measures and how well were they achieved? (03:34-04:45)
5. What were the conclusions of the investigators and what questions remain unanswered? (04:45-05:57)
Speaker Disclosure: Gian Paolo Fadini is a consultant for Novo Nordisk, Sanofi, Lilly and Abbott. He has received lecture fees from Abbott, Astra Zeneca, Boehinger, Lilly, MSD, Novo Nordisk, Takeda and Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Louise Taylor.
Filmed in coverage of the EASD Annual Meeting 2021
